nonhormonal treatment for endometriosis
A single management article asserts that nonhormonal treatment is vital in managing painful symptoms of endometriosis, without supporting quantitative trial data.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 4 of 10 overall, a emerging reading, from a direct rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Only a single source is cited (one review/article on medical management of endometriosis), and it provides only a general assertion rather than corroborated trial data. A single non-synthesis source scores 0.
Rigor
The claim derives from a narrative/management article asserting that nonhormonal treatment is 'vital,' with no described RCT, meta-analysis, or quantitative outcome. This places it at observational/expert-statement level, not a rigorous controlled design.
Specificity
Both the intervention ('nonhormonal treatment') and the condition ('endometriosis') are named directly in the quote and source title. The match is explicit.
Plausibility
The claim merely asserts nonhormonal treatment is vital in managing painful symptoms without describing any mechanism. No mechanistic pathway is provided or evidenced.
Consistency
Only a single source is available, so direction of effect cannot be cross-compared. Per the rule, a single study is scored 1 (n/a, not penalized).
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1hormonal and nonhormonal treatment, is vital in managing painful symptoms PubMed · PMID 39159261 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →